Intercept Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

Intercept Pharmaceuticals

31/07/2023 19:33

* Intercept Pharmaceuticals Inc  ICPT.OQ   ICPT.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 2. 
    * The Morristown New Jersey-based  company is expected to
report 
a 10.9% increase in revenue to $79.567 million from $71.76
million a year ago, according to the mean estimate from 15
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Intercept
Pharmaceuticals
Inc is for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Intercept
Pharmaceuticals Inc is $14.5​, above​ its last closing price
of $10.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.64       -0.65      -0.77     Missed  -18.9
 Dec. 31 2023  0.25        -0.16      -0.50     Missed  -209.7
 Sep. 30 2022  5.79        4.61       7.80      Beat    69.3​
 Jun. 30 2022  -0.39       -0.49      -0.68     Missed  -39.5
 ​​Mar.        -0.80       -0.90      -0.58     Beat    35.7
 31 2022                                                
 Dec. 31 2021  -0.98       -1.10      -1.23     Missed  -12.1​
 Sep. 30 2021  -1.06       -1.09      -0.63     Beat    42.2
 Jun. 30 2021  -1.20       -1.22      -0.33     Beat    72.9
 This summary was machine generated July 31 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated